Biovail Announces Closing of Acquisition of Worldwide Rights to Tetrabenazine Biovail Corporation announced that a wholly owned subsidiary has completed the acquisition of the worldwide development and commercialization rights to the entire portfolio of tetrabenazine products, including Xenazine/Nitoman, and the associated intellectual property rights held by Cambridge Laboratories Limited and its affiliates. [more...]
